Mark Kubik

Also affiliated with University of Pittsburgh Medical Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).”.

Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.6018

N/A

0DataRank · unranked

17 citations

William E. Gooding, Simion I. Chiosea, Umamaheswar Duvvuri, Seungwon Kim, Mark Kubik +8 more

547 Reprogramming of type I interferon-responding tumor-reactive T lymphocytes associates with improved outcomes to neoadjuvant doublet immunotherapy in HNSCC

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0547

N/A

0DataRank · unranked

0 citations

P.M.L. Santos, Aditi Kulkarni, Brian R. Isett, Joy Marion, Simion I. Chiosea +8 more